Your browser doesn't support javascript.
loading
Time-dependent changes in mortality and transformation risk in MDS.
Pfeilstöcker, Michael; Tuechler, Heinz; Sanz, Guillermo; Schanz, Julie; Garcia-Manero, Guillermo; Solé, Francesc; Bennett, John M; Bowen, David; Fenaux, Pierre; Dreyfus, Francois; Kantarjian, Hagop; Kuendgen, Andrea; Malcovati, Luca; Cazzola, Mario; Cermak, Jaroslav; Fonatsch, Christa; Le Beau, Michelle M; Slovak, Marilyn L; Levis, Alessandro; Luebbert, Michael; Maciejewski, Jaroslaw; Machherndl-Spandl, Sigrid; Magalhaes, Silvia M M; Miyazaki, Yasushi; Sekeres, Mikkael A; Sperr, Wolfgang R; Stauder, Reinhard; Tauro, Sudhir; Valent, Peter; Vallespi, Teresa; van de Loosdrecht, Arjan A; Germing, Ulrich; Haase, Detlef; Greenberg, Peter L.
Afiliação
  • Pfeilstöcker M; Hanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria;
  • Tuechler H; L. Boltzmann Institute for Leukemia Research, Vienna, Austria;
  • Sanz G; Hospital Universitario La Fe, Valencia, Spain;
  • Schanz J; Georg August Universität, Göttingen, Germany;
  • Garcia-Manero G; The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Solé F; Institut de Recerca contra la Leucèmia Josep Carreras, Barcelona, Spain;
  • Bennett JM; James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY;
  • Bowen D; St James's University Hospital, Leeds, United Kingdom;
  • Fenaux P; Hopital Avicenne, Assistance Publique-Hopitaux de Paris (AP-HP)/University of Paris XIII, Bobigny, France;
  • Dreyfus F; Hopital Cochin, AP-HP, University of Paris V, Paris, France;
  • Kantarjian H; The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Kuendgen A; Heinrich-Heine University Hospital, Düsseldorf, Germany;
  • Malcovati L; Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy;
  • Cazzola M; Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy;
  • Cermak J; Institute of Hematology and Blood Transfusion, Praha, Czech Republic;
  • Fonatsch C; Medical University of Vienna, Vienna, Austria;
  • Le Beau MM; University of Chicago Comprehensive Cancer Research Center, Chicago, IL;
  • Slovak ML; Department of Pathology, University of New Mexico, Albuquerque, NM;
  • Levis A; Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy;
  • Luebbert M; University of Freiburg Medical Center, Freiburg, Germany;
  • Maciejewski J; Cleveland Clinic, Cleveland, OH;
  • Machherndl-Spandl S; Elisabethinen Hospital, Linz, Austria;
  • Magalhaes SM; Federal University of Ceara, Fortaleza, Brazil;
  • Miyazaki Y; Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • Sekeres MA; Cleveland Clinic, Cleveland, OH;
  • Sperr WR; Division of Hematology, Medical University of Vienna, Vienna, Austria;
  • Stauder R; University Hospital of Innsbruck, Innsbruck, Austria;
  • Tauro S; University of Dundee, Dundee, United Kingdom;
  • Valent P; Division of Hematology, Medical University of Vienna and L. Boltzmann Cluster Oncology, Vienna, Austria;
  • Vallespi T; Hospital Universitario Vall d'Hebron, Barcelona, Spain;
  • van de Loosdrecht AA; Vrije Universiteit Medical Center, Amsterdam, The Netherlands; and.
  • Germing U; Heinrich-Heine University Hospital, Düsseldorf, Germany;
  • Haase D; Georg August Universität, Göttingen, Germany;
  • Greenberg PL; Stanford Cancer Institute, Stanford, CA.
Blood ; 128(7): 902-10, 2016 08 18.
Article em En | MEDLINE | ID: mdl-27335276
ABSTRACT
In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Transformação Celular Neoplásica Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Transformação Celular Neoplásica Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Blood Ano de publicação: 2016 Tipo de documento: Article